MDA-MB-231 cells expressed a very low amount of METTL3 and cell growth inhibition by metformin was weaker than other breast cancer cell lines, further confirming the specificity of miR-483-3p/METTL3 axis as a target for metformin in breast cancer. The gene discussed is METTL3; the disease is breast carcinoma.